Stellarex Vascular E-Registry

NCT ID: NCT02769273

Last Updated: 2025-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1900 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-06-30

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, international, multi-center, single arm, observational study to continue to assess the treatment by the Stellarex™ OTW Drug-coated Angioplasty Balloon in superficial femoral and/or popliteal arteries according to the Instructions for Use in a broad, real-world, claudicant or ischemic rest pain patients population per the institution's standard practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

RCC 2-3

Percutaneous Transluminal Angioplasty

Intervention Type DEVICE

Cohort 2

RCC 4-6 (CLI)

Percutaneous Transluminal Angioplasty

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Percutaneous Transluminal Angioplasty

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Stellarex™ OTW Drug-coated Angioplasty Balloon

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients intended to be treated with Stellarex for de-novo or restenotic lesions of the femoro-popliteal arteries
* Rutherford Clinical Category (RCC) 2-3 or 4 indicated for a Percutaneous Transluminal Angioplasty according to local applicable guidelines
* Patients intended to be treated with Stellarex for de-novo or restenotic lesions of the superficial femoral, popliteal and/or infra-popliteal arteries\*
* Rutherford Clinical Category (RCC) 2-6 indicated for a Percutaneous Transluminal Angioplasty according to local applicable guidelines
* Age ≥18 years old
* Life expectancy \> 1 year
* Is able and willing to provide written informed consent prior to enrollment in the study (as applicable)
* Is able and willing to come on site or to be contacted by phone for the follow-up

Exclusion Criteria

Patients with any medical condition that would make him/her inappropriate for treatment with Stellarex as per Instructions for Use (IFU) or investigator's opinion

* Patient already enrolled in other investigational (interventional) studies that would interfere with study endpoints
* Patients with severe disease of foot circulation defined as:

* "desert foot" (absence of any angiographically visible arterial network below the ankle)
* Or lack of a patent (\<50%DS) and hemodynamically relevant wound related arterial pathway in the foot
* Patients confined to bed that are completely non ambulatory
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Spectranetics Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University Graz

Graz, , Austria

Site Status

Krankenhaus der Barmherzigen Schwesterrn Reid

Ried im Innkreis, , Austria

Site Status

Krankenhaus Göttlicher Heiland GmbH

Vienna, , Austria

Site Status

UZA Antwerpen

Edegem, Edegem, Belgium

Site Status

OLV Aalst

Aalst, , Belgium

Site Status

Imelda

Bonheiden, , Belgium

Site Status

Europe Hospital

Brussels, , Belgium

Site Status

AZ Sint Blasius

Dendermonde, , Belgium

Site Status

Universitair Ziekenhuis Gent

Ghent, , Belgium

Site Status

Jessa Ziekenhuis Hasselt

Hasselt, , Belgium

Site Status

AZ Groeninge

Kortrijk, , Belgium

Site Status

H.Hart Tienen

Tienen, , Belgium

Site Status

Clinique Générale Annecy

Annecy, , France

Site Status

Clinique Rhone Durance

Avignon, , France

Site Status

Clinique Saint Augustin

Bordeaux, , France

Site Status

Clinique Tivoli

Bordeaux, , France

Site Status

Clinique Médipole De Savoie

Challes-les-Eaux, , France

Site Status

Grand Hôpital de l'Est Francilien - Site de Marne la Vallée

Jossigny, , France

Site Status

Groupe hospitalier Saint Joseph

Paris, , France

Site Status

Polyclinique de la Baie

Saint-Martin-des-Champs, , France

Site Status

Clinique Pasteur

Toulouse, , France

Site Status

Clinique Sarrus teinturiers Rive Gauche

Toulouse, , France

Site Status

Klinikum Arnsberg

Arnsberg, , Germany

Site Status

Ev. Krankenhaus Königin Elisabeth Herzberge

Berlin, , Germany

Site Status

MediClin Herzzentrum Coswig

Coswig, , Germany

Site Status

Klinikum Doebeln GmbH

Döbeln, , Germany

Site Status

Cardioangiologisches Centrum Bethanien

Frankfurt, , Germany

Site Status

Krankenhäuser Landkreis Freudenstadt GmbH

Freudenstadt, , Germany

Site Status

Universitätsklinikum Halle

Halle, , Germany

Site Status

Asklepios Klinikum Harburg

Hamburg, , Germany

Site Status

Universitätsklinikum Jena

Jena, , Germany

Site Status

Städtisches Klinikum Karlsruhe gGmbH

Karlsruhe, , Germany

Site Status

Universitätsklinikum Leipzig

Leipzig, , Germany

Site Status

Saint Vincenz Hospital

Limburg, , Germany

Site Status

St. Franziskus-Hospital GmbH

Münster, , Germany

Site Status

Âzienda Ospedaliera Per L'emergenza Cannizzaro

Catania, , Italy

Site Status

AZ Ospedaliera M. Mellini Chiari

Chiari, , Italy

Site Status

Clinica Montevergine

Mercogliano, , Italy

Site Status

Ospedale Civile Di Mirano

Mirano, , Italy

Site Status

Multimedica

Sesto San Giovanni, , Italy

Site Status

"Villa Berica" Gruppo Garofalo

Vicenza, , Italy

Site Status

The Royal Bournemouth Hospital

Bournemouth, , United Kingdom

Site Status

North Bristol NHS Trust

Bristol, , United Kingdom

Site Status

Stoke Mandeville Hospital

Buckingham, , United Kingdom

Site Status

"Saint George's Vascular Institute

London, , United Kingdom

Site Status

Royal Free Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Belgium France Germany Italy United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Gray WA, Jaff MR, Parikh SA, Ansel GM, Brodmann M, Krishnan P, Razavi MK, Vermassen F, Zeller T, White R, Ouriel K, Adelman MA, Lyden SP. Mortality Assessment of Paclitaxel-Coated Balloons: Patient-Level Meta-Analysis of the ILLUMENATE Clinical Program at 3 Years. Circulation. 2019 Oct;140(14):1145-1155. doi: 10.1161/CIRCULATIONAHA.119.040518. Epub 2019 Sep 30.

Reference Type DERIVED
PMID: 31567024 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D029260

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Zilver® PTX™ Global Registry
NCT01094678 COMPLETED NA